No Sweat – Hyperhidrosis Patients Seek Broader Approvals; Botox Access An Issue
Executive Summary
US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.
You may also be interested in...
Dermira Leans On Patient Experience With Hyperhidrosis As It Readies For Qbrexza Launch
Chief Commercial Officer Lori Lyons-Williams tells Scrip that patient stories were the tipping point for many payers considering Qbrexza's $550 per month price. Dermira's also catering to patients with co-pay assistance and a commitment not to raise pricing until after 2019.
Patient-Reported Outcome Data Helps Dermira’s Hyperhidrosis Drug Qbrexza Win US FDA Nod
Co-primary endpoint was Axillary Sweating Daily Diary, a novel PRO instrument developed by Dermira with FDA input, assessed sweating severity and impact of sweating on a person’s daily activities; results complemented quantitative measure of sweat production in Phase III trials.
Dermira Wins First FDA Approval, Preps Qbrexza For October Launch In Hyperhidrosis
The company shifted attention in March from its big acne setback to its mid-year Qbrexza approval, so with a recent FDA nod for the hyperhidrosis treatment, Dermira will fill out its sales team and make the topical product for excessive underarm sweating available in October.